ERBB2 and breast carcinoma: However, it was also reported to exert its antimetastatic role in breast cancer and renal cell carcinoma progression41,42, and a low level of FBXO22 in tumor tissues predicts a poor outcome in ER-positive/HER2-negative breast cancers43.